
EBV EBNA3 577-584, SVRDRLARL
Description
About EBV EBNA3 577-584, SVRDRLARL
The Epstein-Barr Virus (EBV) (strain AG876) Epstein-Barr nuclear antigen (EBNA) 3 Peptide (IEDB: 62305) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Epstein-Barr nuclear antigen (EBNA) Peptide, H-SVRDRLARL-OH (Uniprot: Q69138 aa: 577-584) from JPT is produced under strict quality control and quality management.
EBV EBNA3 577-584, SVRDRLARL - Specifications
- Peptide sequence: H-SVRDRLARL-OH
- Amount: 10 mg (10 x 1 mg)
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Infection, Arthritis
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Request a Quote for you custom antigen peptide!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for EBV EBNA3 577-584, SVRDRLARL
References:
Read References with JPT’s Antigen Peptides
EBV EBNA3 577-584, SVRDRLARL has been described in:
A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers., J Immunol, 1999 (PMID: 9973448)
Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis., Clin Exp Immunol, 2003 (PMID: 12653848)
Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade., Front Immunol, 2022 (PMID: 35874702)
Documentation
Documentation for EBV EBNA3 577-584, SVRDRLARL
Properties
Properties of EBV EBNA3 577-584, SVRDRLARL
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Arthritis, Infection |
Layout: | Freeze-dried in glass vial |
Organism: | Epstein-Barr Virus (EBV) |
Protein Name: | Epstein-Barr nuclear antigen (EBNA) |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to EBV EBNA3 577-584, SVRDRLARL
Information | Values |
---|---|
Sequence: | H-SVRDRLARL-OH |
Specifications: | 9mer peptide as TFA salt |